You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Sapanisertib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Sapanisertib?

Sapanisertib is an investigational drug.

There have been 24 clinical trials for Sapanisertib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 28th 2016.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., and M.D. Anderson Cancer Center.

There are ninety-three US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Sapanisertib
TitleSponsorPhase
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerCalithera Biosciences, IncPhase 2
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyNational Cancer Institute (NCI)Phase 1/Phase 2
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyM.D. Anderson Cancer CenterPhase 1/Phase 2

See all Sapanisertib clinical trials

Clinical Trial Summary for Sapanisertib

Top disease conditions for Sapanisertib
trials0123456789101112CarcinomaNeoplasmsLung NeoplasmsCarcinoma, Non-Small-Cell Lung[disabled in preview]
Top clinical trial sponsors for Sapanisertib
trials0246810121416National Cancer Institute (NCI)Millennium Pharmaceuticals, Inc.M.D. Anderson Cancer Center[disabled in preview]

See all Sapanisertib clinical trials

US Patents for Sapanisertib

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Sapanisertib ⤷  Subscribe Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) ⤷  Subscribe
Sapanisertib ⤷  Subscribe Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Subscribe
Sapanisertib ⤷  Subscribe Method of targeting glycoproteins to treat cancer Board of Regents of the University of Nebraska (Lincoln, NE) ⤷  Subscribe
Sapanisertib ⤷  Subscribe Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use Signal Pharmaceuticals, LLC (San Diego, CA) ⤷  Subscribe
Sapanisertib ⤷  Subscribe Heterocyclic estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 5 of 5 entries

International Patents for Sapanisertib

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Sapanisertib Australia AU2014348657 2033-11-13 ⤷  Subscribe
Sapanisertib Australia AU2017245411 2033-11-13 ⤷  Subscribe
Sapanisertib Australia AU2019246853 2033-11-13 ⤷  Subscribe
Sapanisertib Brazil BR112016010716 2033-11-13 ⤷  Subscribe
Sapanisertib Canada CA2929181 2033-11-13 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 5 of 5 entries

Development Update and Market Projection for Sapanisertib

Introduction

Sapanisertib, a next-generation oral kinase inhibitor targeting mTOR complexes 1 and 2, has been at the forefront of clinical research for various cancer types, particularly in non-small cell lung cancer (NSCLC) and other malignancies with high unmet needs. Here, we delve into the recent developments and market projections for this promising drug candidate.

Clinical Trials and Development Progress

NSCLC Trials

Calithera Biosciences has made significant strides in the development of sapanisertib, particularly in NSCLC. A key study involves the combination of sapanisertib with telaglenastat, an inhibitor of glutaminase, in patients with NSCLC. After evaluating five combination dosing levels in 13 patients, researchers determined that the sapanisertib/telaglenastat combination is safe and tolerable at the recommended expansion dose[1].

This combination has shown promising results, with tumor shrinkage observed in the majority of evaluable patients, including those with lung cancers harboring KEAP1 or NRF2 mutations. The study plans to enroll patients into expansion cohorts to further evaluate the efficacy of this combination in squamous NSCLC with and without NRF2 or KEAP1 mutations, and in adenocarcinoma NSCLC with KRAS and KEAP1 or NRF2 mutations[1].

Phase 2 Clinical Trial in NRF2-Mutated Squamous NSCLC

Calithera Biosciences has also initiated a phase 2 clinical trial for sapanisertib in relapsed/refractory NRF2-mutated squamous NSCLC. This study aims to confirm the selective activity of sapanisertib in NRF2-mutated tumors compared to wild-type tumors and to refine the dose for this patient population. The enrollment of the first patient in this study marks a significant milestone for the program, with data expected to be shared by the first quarter of 2023[5].

Safety and Efficacy

Safety Profile

The safety profile of sapanisertib, particularly when combined with telaglenastat, has been a focus of recent studies. The combination has been found to be safe and tolerable at the recommended expansion dose, with no significant adverse effects reported that would preclude further development[1].

Efficacy in NSCLC

The efficacy of sapanisertib in NSCLC, especially in patients with NRF2 or KEAP1 mutations, has shown promising results. Tumor shrinkage was observed in the majority of evaluable patients, indicating potential therapeutic benefit in these hard-to-treat populations[1].

Market Projections

Global NSCLC Market

The global NSCLC market is projected to grow significantly, driven by the increasing incorporation of premium-priced therapies, including immune checkpoint inhibitors and targeted therapies. By 2025, the NSCLC market is expected to reach $26.8 billion in the 8 major markets (8MM), with a Compound Annual Growth Rate (CAGR) of 15.7%[2].

Role of Sapanisertib

Sapanisertib, if approved, could capture a significant share of this growing market, particularly in the segment of patients with NRF2-mutated squamous NSCLC. Given its potential to be a first-in-class treatment for this patient population, sapanisertib could address a high unmet need and thus command a premium price[1][5].

Competitive Landscape

Immune Checkpoint Inhibitors

The NSCLC market is currently dominated by immune checkpoint inhibitors such as Keytruda (pembrolizumab), Opdivo (nivolumab), and Tecentriq (atezolizumab), which are projected to achieve blockbuster status by 2025. However, targeted therapies, including those like sapanisertib, are expected to contribute significantly to the market growth[2].

Targeted Therapies

Targeted therapies, such as Tagrisso (osimertinib) and Avastin (bevacizumab), are also expected to drive market growth. Sapanisertib, with its unique mechanism of action targeting mTOR complexes, could carve out a niche in the treatment algorithm for NSCLC, especially in biomarker-defined populations[2].

Challenges and Barriers

Patent Expirations

The NSCLC market faces challenges from patent expirations of several blockbuster drugs, which could lead to increased competition from generics. However, innovative therapies like sapanisertib, which target specific biomarkers, are less likely to be impacted by generic competition in the near term[2].

Clinical Trial Outcomes

While sapanisertib has shown promise in NSCLC, it is important to note that it did not meet the primary endpoint in a phase I/II trial for anaplastic thyroid carcinoma (ATC) and radioiodine refractory differentiated thyroid carcinoma (DTC). This highlights the need for continued clinical trials with alternative therapeutic strategies to fully realize its potential[3].

Key Takeaways

  • Safety and Efficacy: Sapanisertib, especially in combination with telaglenastat, has shown a safe and tolerable profile with promising efficacy in NSCLC patients with NRF2 or KEAP1 mutations.
  • Market Potential: The global NSCLC market is projected to grow significantly, and sapanisertib could capture a substantial share by addressing a high unmet need in NRF2-mutated squamous NSCLC.
  • Competitive Landscape: Sapanisertib will compete with established immune checkpoint inhibitors and targeted therapies but has the potential to carve out a niche in biomarker-defined populations.
  • Challenges: The drug faces challenges from patent expirations of other blockbusters and the need for successful clinical trial outcomes to fully realize its market potential.

FAQs

Q: What is the current status of sapanisertib in clinical trials? A: Sapanisertib is currently in phase 2 clinical trials for relapsed/refractory NRF2-mutated squamous NSCLC and is being evaluated in combination with telaglenastat for NSCLC patients with specific mutations[1][5].

Q: What are the key findings from the combination trial of sapanisertib and telaglenastat? A: The combination has been found to be safe and tolerable, with tumor shrinkage observed in the majority of evaluable patients, including those with KEAP1 or NRF2 mutations[1].

Q: How does sapanisertib fit into the current NSCLC treatment landscape? A: Sapanisertib targets a specific biomarker-defined population and could offer a first-in-class treatment option for patients with NRF2-mutated squamous NSCLC, addressing a high unmet need[1][5].

Q: What are the market projections for the NSCLC market by 2025? A: The global NSCLC market is projected to reach $26.8 billion by 2025, with a CAGR of 15.7% driven by the adoption of premium-priced therapies[2].

Q: What challenges does sapanisertib face in the market? A: Sapanisertib faces challenges from patent expirations of other blockbusters and the need for successful clinical trial outcomes to fully realize its market potential[2][3].

Sources

  1. Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences - BioSpace
  2. NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025 - GlobalData
  3. A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory thyroid carcinoma - PubMed
  4. Calithera Biosciences Inc - CALA Stock News - StockTitan
  5. Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2/NFE2L2-Mutated Squamous Non-Small Cell Lung Cancer - BioSpace

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.